Literature DB >> 10735902

Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia.

S Le Gouill1, P Talmant, N Milpied, A Daviet, M Ancelot, P Moreau, J L Harousseau, R Bataille, H Avet-Loiseau.   

Abstract

PURPOSE: To evaluate the usefulness of fluorescence in situ hybridization (FISH) on peripheral-blood specimens to evaluate the cytogenetic response to treatment in patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: In a first attempt, we analyzed 62 bone marrow specimens using interphase FISH and compared the results with those of conventional cytogenetics. In a second step, we analyzed 60 paired sets of bone marrow and peripheral-blood specimens with interphase FISH.
RESULTS: The results of interphase FISH agreed with conventional cytogenetics on bone marrow for most patients, and only minor differences were found (r =.98). The comparison of interphase FISH on bone marrow versus peripheral-blood specimens showed a strong correlation between these two specimen sources (r =.97).
CONCLUSION: Our results confirmed that FISH is a sensitive technique for the evaluation of response to treatment in patients with CML. Moreover, our study suggests that follow-up of cytogenetic response to therapy can be evaluated on peripheral-blood specimens, thus enabling an easier and more frequent evaluation of patients. The next step will be to evaluate this technique in a large prospective trial to define the prognostic value of complete remissions evaluated by FISH.

Entities:  

Mesh:

Year:  2000        PMID: 10735902     DOI: 10.1200/JCO.2000.18.7.1533

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management.

Authors:  W King; J Proffitt; L Morrison; J Piper; D Lane; S Seelig
Journal:  Mol Diagn       Date:  2000-12

2.  Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.

Authors:  You Kyoung Lee; Dong Wha Lee; Yoo Li Kim; Seok Lee; Chang Ki Min; Yoo-Jin Kim; Il-Hoan Oh; Tai-Gyu Kim; Chun Choo Kim; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.

Authors:  Naoto Takahashi; Ikuo Miura; Yoshimi Kobayashi; Masaaki Kume; Tomoko Yoshioka; Wataru Otane; Kaori Ohtsubo; Kaoru Takahashi; Atsushi Kitabayashi; Yoshinari Kawabata; Makoto Hirokawa; Hirokazu Nishijima; Ryo Ichinohasama; John Decoteau; Akira B Miura; Ken-Ichi Sawada
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 4.  Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.

Authors:  Vivian G Oehler; Jerald P Radich
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 5.  Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.

Authors:  Jeffrey A Zonder; Charles A Schiffer
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

6.  A Preliminary Study of the Suitability of Archival Bone Marrow and Peripheral Blood Smears for Diagnosis of CML Using FISH.

Authors:  Alice Charwudzi; Edeghonghon E Olayemi; Ivy Ekem; Olufunmilayo Olopade; Mariann Coyle; Amma Anima Benneh; Emmanuel Alote Allotey
Journal:  Adv Hematol       Date:  2014-09-22

7.  Reliability Evaluation of Fluorescence In Situ Hybridization (FISH) and G-Banding on Bone Marrow and Peripheral Blood Cells in Chronic Myelogenous Leukemia Patients.

Authors:  Soheila Manaflouyan Khajehmarjany; Seyed Ali Rahmani; Seyed Hadi Chavoshi; Ali Esfahani; Ali Akbar Movassaghpour Akbari
Journal:  Cell J       Date:  2015-04-08       Impact factor: 2.479

8.  On the Power of Additional and Complex Chromosomal Aberrations in CML.

Authors:  Karin M Greulich-Bode; Barbara Heinze
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.